CD40 rs1883832基因多态性与癌症易感性之间的关联:系统评价与荟萃分析。
完整摘要 · 中文译文
CD40基因是一种关键的免疫调节分子,已被认为与肿瘤发生有关,其位于Kozak序列的功能性多态性rs1883832可能通过影响CD40表达来调节癌症易感性。为阐明不一致的流行病学研究结果,开展了一项综合荟萃分析,以评估CD40 rs1883832多态性与总体癌症风险之间的关联。从PubMed、Web of Science和Cochrane Library系统检索截至2025年8月15日的合格病例对照研究,并在五种遗传模型下计算合并比值比(OR)及其95%置信区间(CI)。八项研究共纳入3858例癌症病例和4699例对照,符合纳入标准。结果显示,rs1883832 T等位基因与癌症风险升高在4种多模型中存在显著关联,包括等位基因模型(T vs. C:OR = 1.26,95% CI:1.09-1.47,p < 0.01)、纯合子模型(TT vs. CC:OR = 1.58,95% CI:1.16-2.16,p < 0.01)、隐性模型(TT vs. TC + CC:OR = 1.43,95% CI:1.18-1.82,p < 0.01)和显性模型(TT + TC vs. CC:OR = 1.29,95% CI:1.03-1.62,p = 0.03)。亚组分析显示,在肺癌和亚洲人群中存在提示性关联模式。敏感性分析证实了这些结果的稳健性,且未检测到明显的发表偏倚。总之,本荟萃分析提供了有力证据,表明CD40 rs1883832 T等位基因可能增加癌症易感性,从而强调了免疫基因多态性在癌变中的潜在影响。 及其在肿瘤学遗传风险评估中的相关性。试验注册:PROSPERO注册号:CRD420251130223。
完整摘要 · 英文原文
The CD40 gene, a key immune regulatory molecule, has been implicated in tumorigenesis, and its functional polymorphism rs1883832 located in the Kozak sequence, may modulate cancer susceptibility by influencing CD40 expression. To clarify inconsistent epidemiological findings, a comprehensive meta-analysis was conducted to evaluate the association between the CD40 rs1883832 polymorphism and overall cancer risk. Eligible case-control studies were systematically identified from PubMed, Web of Science and Cochrane Library up to August 15, 2025, and pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated under five genetic models. Eight studies encompassing 3858 cancer cases and 4699 controls met the inclusion criteria. The results revealed a significant association between the rs1883832 T allele and elevated cancer risk in 4 multiple models, including the allele (T vs. C: OR = 1.26, 95% CI: 1.09-1.47, p < 0.01), homozygous (TT vs. CC: OR = 1.58, 95% CI: 1.16-2.16, p < 0.01), recessive (TT vs. TC + CC: OR = 1.43, 95% CI: 1.18-1.82, p < 0.01), and dominant (TT + TC vs. CC: OR = 1.29, 95% CI: 1.03-1.62, p = 0.03) models. Subgroup analyses revealed suggestive patterns of associations in lung cancer and Asian populations. Sensitivity analyses confirmed the robustness of these findings, and no substantial publication bias was detected. In conclusion, this meta-analysis provides compelling evidence that the CD40 rs1883832 T allele may confer increased susceptibility to cancer, thereby underscoring the potential influence of immune gene polymorphisms in carcinogenesis and their relevance for genetic risk assessment in oncology. Trial Registration: PROSPERO number: CRD420251130223.